Blogs

Latest Blogs

EBF OS 2025: My Key Highlights

December 10, 2025

A unifying message across EBF 2025 was that bioanalytical science is transitioning from technical execution to decision support. For years, our industry has focused on…

Establishing Biosimilarity: Regulatory and Scientific Expectations

June 5, 2025

A biosimilar is defined as a biologic product, highly similar to a reference or originator, with no clinically meaningful differences…

Why The Future Of Precision Medicine Will Be Defined By The Quality And Strategy Of Biomarker Signatures

May 15, 2025

We’re in the midst of a paradigm shift in biomarker science. No longer academic luxuries or exploratory afterthoughts, biomarker signatures…

Radiopharmaceutical Drug Development: A Bioanalytical Lab Perspective

May 8, 2025

The radiopharmaceutical industry has traditionally experienced steady but modest growth, primarily driven by its established role in diagnostics and nuclear…

Building a bioanalytical workflow for a vaccine study: The key assays and considerations

March 12, 2025

The COVID-19 pandemic put vaccines under the spotlight again, and from a scientific perspective at least, innovations have abounded.…

Quantitative Analysis of Oligonucleotides: An out of the box LC-MS/MS approach

March 5, 2025

Oligonucleotide therapeutics have revolutionised the field of medicine over the last decade due to their potential for treating a broad…

The Next Frontier for CAR T-Cell Therapy: Shifting Gears to Autoimmune Conditions

February 18, 2025

CAR T-cell therapy has transformed cancer treatment, offering new hope for patients with aggressive B cell malignancies like acute lymphoblastic…